TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J, et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754